scispace - formally typeset
M

Martin Ridderstråle

Researcher at Lund University

Publications -  124
Citations -  22978

Martin Ridderstråle is an academic researcher from Lund University. The author has contributed to research in topics: Type 2 diabetes & Insulin. The author has an hindex of 35, co-authored 120 publications receiving 20479 citations. Previous affiliations of Martin Ridderstråle include Steno Diabetes Center & Scania AB.

Papers
More filters
Journal ArticleDOI

40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004.

M Veitenhansl, +5467 more
- 01 Aug 2004 - 
Journal ArticleDOI

Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial

TL;DR: The EMPA‐REG H2H‐SU trial in patients with type 2 diabetes with inadequate glycaemic control on metformin provided a sustained reduction in glycated haemoglobin (HbA1c) with a small but statistically significant benefit vs glimepiride, sustained reductions in weight and blood pressure, and low risk of hypoglycaemia.
Journal ArticleDOI

Genetic Variance in the Adiponutrin Gene Family and Childhood Obesity

TL;DR: Genetic variation in the adiponutrin gene family does not seem to contribute strongly to obesity in children and adolescents, and PNPLA1 exhibited a modest effect on obesity and PnPLA3 on insulin sensitivity.
Journal ArticleDOI

Genetic and Nongenetic Regulation of CAPN10 mRNA Expression in Skeletal Muscle

TL;DR: Evidence that mRNA expression of CAPN10 in skeletal muscle is under genetic control is provided, as glucose-tolerant but not glucose-intolerant individuals upregulate theirCAPN10 mRNA levels in response to prolonged exposure to fat.
Journal ArticleDOI

Metabolite profiling of obese individuals before and after a one year weight loss program

TL;DR: Diet-induced weight loss leads to mainly reduced levels of metabolites that are elevated in obese insulin resistant individuals and levels of specific metabolites, such as xylitol, may be predictive of the response to non-surgical weight loss already at baseline.